跳至主要内容
临床试验/NCT06586307
NCT06586307已完成不适用

Assessment of DNA Methylation Signatures in Lymphocytes for Evaluating the Efficacy and Prognosis of Immunotherapy in Colorectal Cancer

Sixth Affiliated Hospital, Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2023年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
49
试验地点
1
主要终点
Complete Response Rate

研究概览

简要总结

The goal of this observational study is to assess lymphocyte levels in colorectal cancer patients using DNA methylation levels in tissues or blood. The main questions it aims to answer are:

Can DNA methylation features calculate lymphocyte levels? Can the calculated lymphocyte levels assess the efficacy and prognosis of immunotherapy?

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with colorectal cancer by colonoscopy pathology and deemed eligible for immunotherapy after assessment.
  • Neoadjuvant immunotherapy regimen includes PD-1 or anti-PD-L
  • R0 resection is performed after neoadjuvant immunotherapy.
  • Complete immunotherapy efficacy assessment data and follow-up data are available.
  • The tissue bank stores the required whole blood and tissue samples for the experiment.

排除标准

  • Concurrent other malignancies.
  • Neoadjuvant immunotherapy not conducted according to the standard protocol.
  • Severe adverse chemotherapy reactions that lead to the discontinuation of immunotherapy midway.
  • Lack of complete neoadjuvant chemotherapy efficacy assessment data or follow-up data.
  • The tissue bank does not store the required whole blood or tissue samples for the experiment.
  • Patients with concurrent other immune system diseases.

结局指标

主要结局

Complete Response Rate

时间窗: From the date of neoadjuvant therapy until the date when the surgical specimen pathology results are obtained, the duration of neoadjuvant therapy is approximately half a year, with a maximum of one year.

The complete response rate refers to the percentage of patients who experience a complete disappearance of their disease after treatment.

次要结局

未报告次要终点

研究者

发起方
Sixth Affiliated Hospital, Sun Yat-sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yanxin Luo,MD

Head of Gastroenterology

Sixth Affiliated Hospital, Sun Yat-sen University

研究点 (1)

Loading locations...

相似试验